New Immunotherapy Shows Early Tumor Control

Interim Phase 1 data in 22 heavily pretreated patients show a 59% disease control rate, but the research-stage therapy remains investigational.

Updated on Nov. 6, 2026 in Biotech

Bold vector editorial illustration of a single Y-shaped antibody-like molecule in coral and teal with a mustard signaling protein, surrounded by small immune-cell forms.
Interim Phase 1 data from SOTIO Biotech's VICTORIA-01 study show a 59% disease control rate in 22 heavily pretreated patients taking the investigational therapy SOT201. AI Illustration. Upload story photo >

SOTIO Biotech presented interim safety and efficacy results from its VICTORIA-01 Phase 1 study of SOT201 at the SITC 41st Annual Meeting in Phoenix, Arizona. The early-stage study, in 22 patients with advanced solid tumors, is research-stage and not an approved therapy.

Why it matters

SOT201 pairs an IL-15 superagonist with anti-PD-1 activity, a combination aimed at stimulating tumor-specific T cells in patients who have already progressed on checkpoint inhibitors. Early signals in heavily pretreated patients show where next-generation immunotherapies are being tested.

The interim analysis reports a 59% disease control rate across 22 patients with advanced solid tumors, with a recommended dose of 80 µg/kg preceded by a 20 µg/kg priming dose. One esophageal cancer response has lasted 388 days, and one cervical cancer response was ongoing at 87 days, with most treatment-related adverse events Grade 1 or 2.

The players

SOTIO Biotech

A clinical-stage biopharmaceutical company owned by PPF Group, developing immunocytokine therapies including SOT201.

SITC

The Society for Immunotherapy of Cancer, whose 41st Annual Meeting served as the venue for the VICTORIA-01 data presentation.

MD Anderson

The Houston, Texas cancer center where the presenting investigator is based.

The details

SOT201 is a PD-1 targeting IL-15 immunocytokine, meaning an antibody that binds PD-1 to deliver an interleukin-15 signaling molecule directly to T cells in the tumor environment. IL-15 is a signaling protein that helps expand and sustain immune T cells, while PD-1 is a checkpoint receptor that tumors use to suppress them. The Phase 1 VICTORIA-01 study evaluated this approach in patients with advanced solid tumors to determine safety and an appropriate dose.

Timeline

  1. Nov. 6, 2026: SOTIO presented interim VICTORIA-01 results at SITC 41st Annual Meeting.

  2. Nov. 7, 2026: Poster 1180 on the VICTORIA-01 interim results was presented.

The Tech Race

SOT201 sits in the competitive field of combining checkpoint blockade with cytokine-based immune activation. Its interim data are early and drawn from 22 patients, so the trajectory will depend on results from expanded cohorts the company says it will pursue.

SOT201 remains investigational and is not available to patients outside clinical study settings. The company supports continued evaluation in expanded cohorts, with no approval timeline disclosed in the source.

The takeaway

Watch for results from expanded SOT201 patient cohorts and the company's further characterization in challenging solid tumor types. Those data will show whether the early disease control signal holds beyond a small interim group.

Further reading

Explore more reporting in our Biotech section for context on immunotherapy development.

Source note: This article includes information reported by The Manila times.